Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Janku

Showing results (71-80 of 277) with videos related to

Pageof 28
Sort By:
Molecular Oncology|August 26, 2025
Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomicsMorten Lapin, Kjersti Tjensvoll, Karin Hestnes Edland, et al.
Scientific Reports|February 12, 2021
Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trialJeffrey A How, Amir A Jazaeri, Pamela T Soliman, et al.
Oncotarget|June 27, 2013
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implicationsYunyun Jiang, Filip Janku, Vivek Subbiah, et al.
Cancer|August 9, 2011
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer CenterIgnacio Garrido-Laguna, Filip Janku, Christos Vaklavas, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathiesRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Oncoscience|August 5, 2016
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
The Oncologist|February 23, 2011
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinicFilip Janku, Apostolia M Tsimberidou, Xuemei Wang, et al.
Pageof 28

Showing results (71-80 of 277) with videos related to

Sort By:
Pageof 28
Molecular Oncology|August 26, 2025
Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomicsMorten Lapin, Kjersti Tjensvoll, Karin Hestnes Edland, et al.
Scientific Reports|February 12, 2021
Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trialJeffrey A How, Amir A Jazaeri, Pamela T Soliman, et al.
Oncotarget|June 27, 2013
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implicationsYunyun Jiang, Filip Janku, Vivek Subbiah, et al.
Cancer|August 9, 2011
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer CenterIgnacio Garrido-Laguna, Filip Janku, Christos Vaklavas, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathiesRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Oncoscience|August 5, 2016
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
The Oncologist|February 23, 2011
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinicFilip Janku, Apostolia M Tsimberidou, Xuemei Wang, et al.
Pageof 28